Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole LAI PK in Schizophrenia
NCT05119894Phase 1Withdrawn
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2021
01
Overview
Phase 1, open-label trial of brexpiprazole long-acting injection in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Plasma concentrations of brexpiprazole at Day 182. Planned start Nov 2021; status: withdrawn.
02
Drugs
brexpiprazole long-acting injection
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05119894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119894.